Exercise Hemodynamic, Right Ventricular Coupling and Echocardiography in Pulmonary Hypertension
NCT ID: NCT04663217
Last Updated: 2024-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2020-11-01
2023-11-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Exercise and Respiratory Therapy on Right Ventricular Function in Severe Pulmonary Hypertension
NCT04224012
Influence of Respiratory and Exercise Therapy on Oxygen Uptake, Quality of Life and Right Ventricular Function in Severe Pulmonary Hypertension
NCT01394367
Haemodynamics and Ventricular Arrhythmias During Exercise in Patients With Arrhythmogenic Cardiomyopathy
NCT06823271
RV Systolic and Diastolic Function and Contractile Reserve Under Acute Exercise and in Response to Chronic Exercise-based Rehabilitation
NCT04188756
Aerobic Exercise in Patients With Pulmonary Hypertension
NCT00678821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study comprises a 1-day screening period, followed by a right heart catheterization with exercise challenge.
The study starts with screening, information of the patients and Informed Consent Form signature at day -1. Screening and inclusion of the patient can be performed on the same day. On the day of the planned right heart catheterization based on clinical grounds, exercise right heart catheterisation (RHC) using Swan-Ganz and/or Conductance catheters with simultaneous echocardiography will be performed. End of study is defined as a complete exercise RHC. Adverse events will be assessed until 1 day after the exercise RHC.
After placement of the Swan-ganz or Conductance catheter patients will undergo an exercise challenge using the following protocol in semi-supine position until exhaustion:
* Incremental workload increase of 20Watt every 2-4 min.
* For patients not able to start a 20 Watt, initial workload can be adjusted to a minimum of 5 Watt with 5 Watt increase every 2-4 min until exhaustion
* Maximal exercise duration is 10-12 minutes
* Symptoms of dyspnoea during exercise will be rated by subjects at baseline, after 6 minutes and at maximum according to the Borg perceived dyspnoea (0-10) scale.
Simultaneously, echocardiography and lung ultrasound will be performed before exercise (baseline), after 6 minutes of exercise and at maximum.
After assessment of right ventriclure pressure-volume loops during maximum exercise, guided by echocardiographic the conductance catheter will be placed in the right atrium to obtain right atrium pressure-volume loops during maximum exercise.
Optional, the exercise RHC will be performed without the Conductance catheter and only with the Swan-Ganz catheter. In this case, pressure values and cardiac output will be measured using the thermodilution method, averaging 3-5 measurements at baseline, 6 minutes and maximum. Detailed assessment of right atrial pressure curves (with a and v wave) will be performed at baseline, 6 minutes and maximum exercise.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pulmonary arterial hypertension
Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.
Exercise
After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
Pulmonary hypertension due to left heart disease
Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure above 15 mmHg with left heart disease, classified into group 2 of the clinical classification of pulmonary hypertension.
Exercise
After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
Chronic thromboembolic pulmonary hypertension
Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.
Exercise
After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
Control
Patients with mean pulmonary arterial pressure below 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with exclusion of pulmonary hypertension.
Exercise
After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exercise
After placement of the right heart catheter patients will undergo an exercise challenge in semi-supine position until exhaustion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pulmonary hypertension due to left heart disease (World Health Organization group 2)
* Chronic thromboembolic pulmonary hypertension (World Health Organization group 4)
* Invasive exclusion of pulmonary hypertension
* Age ≥ 18 years
* Planned right heart catheterization based on clinical grounds
* Stable specific PAH medications
* Ability to undergo cycle ergometry
* Signed informed consent
Exclusion Criteria
* Unstable or severe coronary artery disease
* Uncontrolled arterial hypertension
* Left ventricular ejection fraction \< 30%
* Severe congenital or acquired valvular or myocardial disease
* Progressive left heart failure
* History of severe ventricular arrhythmias
* Severe, terminal renal impairment
* Severe obstructive or restrictive lung disease
* Severe lung emphysema or interstitial lung disease
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Giessen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Richter J Manuel, MD
Role: PRINCIPAL_INVESTIGATOR
UKGM Giessen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kerckhoff-Klinik
Bad Nauheim, Hesse, Germany
University of Giessen
Giessen, Hesse, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yogeswaran A, da Rocha BB, Rako ZA, Kaufmann SJ, Schafer S, Kremer N, Ghofrani HA, Seeger W, Tello K. Physiological mechanisms behind respiratory variations in right atrial pressure in pulmonary hypertension. Sci Rep. 2024 May 31;14(1):12547. doi: 10.1038/s41598-024-61825-6.
Rako ZA, Yogeswaran A, Lakatos BK, Fabian A, Yildiz S, da Rocha BB, Vadasz I, Ghofrani HA, Seeger W, Gall H, Kremer NC, Richter MJ, Bauer P, Tedford RJ, Naeije R, Kovacs A, Tello K. Clinical and functional relevance of right ventricular contraction patterns in pulmonary hypertension. J Heart Lung Transplant. 2023 Nov;42(11):1518-1528. doi: 10.1016/j.healun.2023.07.004. Epub 2023 Jul 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AZ 11716
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.